Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 35, 2022 - Issue 3
34
Views
0
CrossRef citations to date
0
Altmetric
Case Studies

Effectiveness of casirivimab/imdevimab in an intensive care unit patient with acute respiratory failure due to SARS-CoV-2 infection

, BA, , PA-C, , MD, MS & , MD, MPH
Pages 339-341 | Received 10 Dec 2021, Accepted 10 Feb 2022, Published online: 03 Mar 2022
 

Abstract

Casirivimab/imdevimab, a cocktail of monoclonal antibodies, is currently approved for emergency use in high-risk ambulatory patients with early COVID-19 to reduce risk of hospitalization and/or death from SARS-CoV-2 infection. In the United States, there is no approved monoclonal antibody therapy for patients hospitalized for complications due to acute SARS-CoV-2 infection. We describe here the use of casirivimab/imdevimab in a 52-year-old fully vaccinated, immunocompromised man admitted to the intensive care unit for acute hypoxemic respiratory failure due to SARS-CoV-2 infection.

Log in via your institution

Log in to Taylor & Francis Online

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 37.00 Add to cart

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.